Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676434 | 0.92 | NR1H4 (0.46) | NR1H4SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL22358096 | 0.86 | NR1H4 (0.46) | NR1H4SMN1; SMN2HTTLMNATSHR | |
| SCHEMBL22357937 | 0.85 | LMNA (0.47) | NR1H4SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL22358347 | 0.85 | — | — | |
| SCHEMBL22357909 | 0.82 | SMN1; SMN2 (0.46) | NR1H4SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL20117136 | 0.82 | TLR9 (0.52) | NR1H4SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL22358169 | 0.82 | LMNA (0.52) | NR1H4SMN1; SMN2HTTLMNATSHR | |
| SCHEMBL22357902 | 0.82 | SMO (0.52) | NR1H4SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL22358342 | 0.82 | NR1H4 (0.51) | NR1H4SMN1; SMN2HTTLMNATSHR | |
| SCHEMBL22358188 | 0.82 | SMN1; SMN2 (0.46) | NR1H4SMN1; SMN2LMNATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NR1H4 1341/4885SMN1; SMN2 13/4885GAA 67/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NR1H4 1341/4885SMN1; SMN2 13/4885GAA 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.